BIOS Capital Management, LP Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0001813845

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth Tilt how tags are computed

Q2 2026 · 6 positions · Total reported value $41.67M · Top-10 concentration 100.0% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 16.7% · 0 new · 1 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -18.0% · vs SPY -20.1% · Prev Value $41.67M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -31.8% · vs SPY -34.0% · Latest Value $34.17B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, BIOS Capital Management, LP disclosed 6 equity positions with a combined reported value of $41.67M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt.

The largest disclosed positions as of Q2 2026 were ACTU ($15.38M), IRD ($15.14M), CGTX ($6.90M). By sector, the heaviest allocations are Health Care 100.0%.

Versus the prior quarter, BIOS Capital Management, LP opened 0 new positions, trimmed 1 and fully exited 0, a turnover rate of 16.7% of positions. The portfolio's overlap with the prior quarter was 100% of names.

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

Insider Transactions (Form 4)

Latest BIOS Capital Management, LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-06-17 Award COGNITION THERAPEUTICS INC 25,000 — SEC filing

All insider transactions →

Fund Profile

BIOS Capital Management, LP is an SEC-registered 13F filer based in Fort Worth, TX, United States. As of Q2 2026 it reported 6 US equity positions with a combined value of $41.67M. HoldingsHub carries 7 quarters of its filings (Q4 2024–Q2 2026).

Firm Snapshot

  • Headquarters: FORT WORTH, TX, United States
  • SEC registration: 801-117544 (status: Approved), registered 2019-10-24
  • Regulatory AUM (Form ADV): $250.90M as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 24 private funds

Portfolio Structure

  • 6 positions · $41.67M reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: ACTU (ACTUATE THERAPEUTICS INC) at 36.9%
  • Average position size: $6.95M

Sector Tilt

  • Health Care 100.0%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 added, 2 reduced
  • 3 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: BIOS Capital Management, LP maintained a cautious stance in the 2026-Q2, with a slight tilt towards active management, as evidenced by their "Hold" actions on the majority of their holdings and a significant increase in one position. 2. Key Moves: - Added/Increased: Rein Therapeutics (RNTX) saw the most significant increase in shares by 50.4% QoQ, indicating a new addition or a substantial increase in existing holdings. - Reduced/Removed: Lantern Pharma (LTRN) and IN8bio (INAB) saw substantial reductions in their shareholdings by 71.1% and 51.8% QoQ, respectively, suggesting a reduction in exposure to these companies. 3. Portfolio Structure: - Passive vs. Active: The fund appears to have an active management approach, given the changes in holdings and the "Add" and "Reduce" actions. - Sector Bias: The portfolio is heavily biased towards the Health Care sector, with all top-10 holdings falling within this category. - Risk Appetite: The portfolio has a moderate risk appetite, as it maintains a significant position in a biotech stock (RNTX) that could be considered high-risk, while also holding onto established healthcare companies. 4. Per-Holding One-Liner: - ACTU (ACTUATE THERAPEUTICS INC): Develops therapies for metabolic and rare diseases. - IRD (OPUS GENETICS INC): Focuses on the development of treatments for genetic diseases. - CGTX (COGNITION THERAPEUTICS INC): Engaged in the development of novel therapies for neurological and psychiatric disorders. - RNTX (REIN THERAPEUTICS INC): A biotechnology company developing treatments for metabolic diseases. - LTRN (LANTERN PHARMA INC): Focuses on novel therapies for orphan diseases. - INAB (IN8bio Inc): A biotechnology company developing cell and gene therapies for a range of indications. - Notes: The one-liners are based on the issuer names and sectors provided. Additional verification may be required for the specific business activities of each company. 5. One-Sentence Style Summary: BIOS Capital Management, LP maintained a diversified healthcare portfolio in Q2 2026, with a focus on active management and a significant increase in exposure to Rein Therapeutics, balancing it with reductions in other holdings.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 100.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 10.05M $15.38M 36.90%
36.90%
Hold
2 3.68M $15.14M 36.33%
36.33%
Hold
3 6.00M $6.90M 16.56%
16.56%
Hold
4 2.98M $3.10M 7.44%
7.44%
Add
5 249.40K $1.04M 2.50%
2.50%
Reduce
6 80.96K $114.15K 0.27%
0.27%
Reduce

FAQ

What did BIOS Capital Management, LP buy in 2026-Q2?

In its 2026-Q2 13F filing, BIOS Capital Management, LP reported 6 equity positions worth $41.67M in aggregate; its largest disclosed positions were ACTU ($15.38M), IRD ($15.14M), CGTX ($6.90M).

How large is BIOS Capital Management, LP's portfolio?

BIOS Capital Management, LP reported $41.67M of long equity holdings across 6 positions as of 2026-Q2. Top-10 holdings account for 100.0% of reported value.

What is BIOS Capital Management, LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/bios-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →